{"id":"W7098140935","doi":"","title":"Re: Hauschild A. Adjuvant interferon alfa for mela- noma: new evidence-based treatment recommenda-","year":2009,"lang":"en","type":"article","venue":"","topic":"HIV/AIDS oral health manifestations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Interferon alfa; Interferon; Adjuvant; Alpha interferon; Melanoma; Cancer; Disease; Clinical trial; Survival analysis","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002270199,0.0002520473,0.0004360044,0.0001706762,0.0001421116,0.00002181695,0.0001035341,0.000104142,0.0007356539],"category_scores_gemma":[0.0002527433,0.0001901932,0.000157266,0.0001994293,0.00002336166,0.00019014,0.00001032111,0.0001343961,0.00006759144],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005155147,"about_ca_system_score_gemma":0.000573737,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006414396,"about_ca_topic_score_gemma":0.0008171352,"domain_scores_codex":[0.9983778,0.00005458904,0.0005182883,0.0004088488,0.0001914233,0.0004490653],"domain_scores_gemma":[0.9983496,0.0004359749,0.0001102088,0.0005006148,0.0001167855,0.0004868237],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.002221339,0.0009218334,0.001104445,0.0001428902,0.00005946171,0.00004589829,0.0005243145,0.00001799352,0.0003690838,0.001244443,0.4163721,0.5769762],"study_design_scores_gemma":[0.0391717,0.124985,0.02942691,0.005489795,0.001734046,0.0001280045,0.001743442,0.01418206,0.02207989,0.003097459,0.7562724,0.001689362],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.04195959,0.002709505,0.04089007,0.8897556,0.0006603755,0.00673936,0.00009967457,0.0006964566,0.01648937],"genre_scores_gemma":[0.8544096,0.000345161,0.08183365,0.0230259,0.0006347871,0.0001690553,0.0003858009,0.00004071799,0.03915531],"genre_candidate":"commentary","genre_consensus":null,"teacher_disagreement_score":0.8667297,"threshold_uncertainty_score":0.8054894,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1508898315036547,"score_gpt":0.4063009706913873,"score_spread":0.2554111391877325,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}